Please note: Timings are in CET (Central European Time) 

  1. Session 4: Sustainability and the BPR
  2. Updates on the high-level round table discussions and the likely impacts of the Reach/CLP reviews on the biocides sector

    Paul Krajnik, Deputy Director, Chair ECHA – Management Board 

  3. Request for the application of specific impacts to be considered to determine essential use

  4. The Blue Angel ecolabel approach to antifouling

    • 100 non-biocidal antifouling systems have been identified for the German market
    • They can be allocated to 14 different mechanisms of action
    • Proofs of concept and banned substances will be presented
    Bernd Daehne Bernd Daehne
    Director of Antifouling Research Station, Dr. Brill + Partner - Institute for Antifouling and Biocorrosion
  5. Q&A

  6. Refreshment break

  7. Session 4: Sustainability and the BPR, continued
  8. The EU Chemical Strategy for Sustainability (CSS): What does it mean for biocides?

    Marcel Hulsman, Partner Product Stewardship, Biocides, ERM 

  9. Legal perspective: Implications of sustainability regulations for companies in the biocides sector

    • Context and drivers for sustainability  
    • Current successes, difficulties and opportunities 
    Koen Van Maldegem Koen Van Maldegem
    Partner, Competition Regulatory and Trade, Fieldfisher LLP, Belgium
    Gerard McElwee Gerard McElwee
    Partner, Fieldfisher, Belgium
  10. Q&A

  11. Lunch

  12. Chemical Watch Demo

  13. Session 5: The assessment of endocrine disrupting chemicals under the BPR
  14. Available testing methods / capacities for identifying endocrine BP active chemicals

  15. Scientific criteria to identify endocrine chemicals

    • What are the new methods and their implementation within regulatory assessment? 
    • How to build the weight of evidence?  
    • Why is mechanistic toxicology required for ED assessment?  
    • Endocrine activity versus adverse outcome?  
    Gregory Lemkine Gregory Lemkine
    CEO, Watchfrog Laboratory
  16. The latest developments and significant legal issues arising on ED assessments

    Darren Abrahams Darren Abrahams
    Partner - Chemical and Life Sciences, Steptoe & Johnson LLP
    Hannah Widemann Hannah Widemann
    Senior Associate - Chemical and Life Sciences, Steptoe & Johnson LLP
  17. Q&A

  18. Refreshment break

  19. Session 6: Efficacy updates
  20. Efficacy evaluation of disinfectants PT 1 to 5, PT 21 and treated articles PT 10 based on current development and Echa efficacy guidance including biofilm-activity testing

    • Overview of current activity test methods for PT 1 – 5, PT 10 and PT 21
    • Current Development regarding Resistance development
    • Biofilm activity methods – Quo vadis?
    Dr Florian H. H. Brill Dr Florian H. H. Brill
    Owner and Managing Director, Dr. Brill + Partner GmbH Institut für Hygiene und Mikrobiologie
  21. Efficacy – beyond the guidance

    David Ashworth David Ashworth
    Managing Director, Klarus Consulting Ltd, UK
  22. Simulated use test and field trial for PT5 claims and applications

    • PT 5 claim matrix and ECHA test requirements
    • Simulated use test: validation requirements (case study: UBA test)
    • Robust field trial experimental design (case study: animal drinking water facility)
    Michele Cavalleri Michele Cavalleri
    Biomed & GLP Facility Manager, Eurofins Biolab
  23. Q&A

  24. End of conference

View previous day / next day